GlassScriptPhysician profile
Uy T Hoang
NPI 1396061099
$14,189.79
in general payments reported to CMS, 2019-2025
32 companies · $2,382 in 2025
The $2,382 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $814 · 2021: $2,022 · 2022: $2,207 · 2023: $2,108 · 2024: $3,180 · 2025: $2,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,494 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,494.45 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,296.10 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,859.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $1,681.49 | 2021-2025 | Otezla, Repatha, Prolia |
| Gilead Sciences, INC. | $1,598.54 | 2019-2025 | Vemlidy, Veklury, Livdelzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,031.99 | 2019-2025 | Ofev, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $794.55 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $717.39 | 2022-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $566.54 | 2023-2025 | |
| La Jolla Pharmaceutical Company | $421.80 | 2024-2025 | Xacduro, Zevtera, Giapreza |
| Novo Nordisk INC | $392.97 | 2022-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $355.03 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $348.57 | 2020-2022 | |
| Pfizer INC. | $328.40 | 2019-2024 | |
| Abbott Laboratories | $219.59 | 2022-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $161.15 | 2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $141.05 | 2023-2025 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $140.94 | 2025 | Terlivaz |
| Redhill Biopharma INC. | $133.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $125.98 | 2019-2022 | |
| Alkermes, INC. | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $121.56 | 2023 | Ultomiris |
| Vertex Pharmaceuticals Incorporated | $119.50 | 2025 | |
| Genzyme Corporation | $113.85 | 2024 | |
| Phadia US INC. | $112.56 | 2021-2022 | |
| Lilly USA, LLC | $74.98 | 2023-2025 | Jardiance, Kisunla, Mounjaro |
| Lundbeck LLC | $58.81 | 2025 | Rexulti |
| Shield Therapeutics INC | $38.46 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $33.45 | 2021 | |
| Esperion Therapeutics, INC. | $24.14 | 2020 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Merck Sharp & Dohme LLC | $16.93 | 2020 | |
| Sanofi Pasteur INC. | $16.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uy Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.